Calls for papers
-
Respira Therapeutics has announced that United Therapeutics will end its collaboration with the company and will return all rights to Respira’s RT234 vardenafil DPI, which is in Phase 2 development for the relief of symptoms… Read more . . .
-
Contract manufacturer Experic, which offers a variety of services related to dry powder inhalers, has named Sherry Ann D’Iorio as Executive Director of Business Development. D’Iorio was most recently Senior Account Director of Business Development at… Read more . . .
-
According to Vectura, the English High Court has dismissed all claims in a “passing off” case brought by GlaxoSmithKline in which GSK charged that of Sandoz’s AirFluSal Forspiro DPI looks too similar to Seretide Accuhaler. Both inhalers and… Read more . . .
-
Milestone Pharmaceuticals has announced the initiation of the Phase 3 NODE-303 open-label safety study of the company’s intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). NODE-303 is the third of three trials in the… Read more . . .
-
Janssen Pharmaceutical said that it has submitted a supplemental new drug application to the FDA requesting to expand the use of Spravato esketamine CIII nasal spray for the treatment of major depressive disorder in patients… Read more . . .
-
Chiesi Farmaceutici has announced results from the Phase 3 TRIGGER and TRIMARAN studies of its CHF 5993 extrafine beclometasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium (G) MDI for the treatment of uncontrolled asthma in patients who have… Read more . . .
-
GlaxoSmithKline and Innoviva announced that GSK has submitted a supplemental new drug application for the use of the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI for the treatment of asthma. The FDA initially approved Trelegy Ellipta for… Read more . . .
-
Savara said that the FDA provided a written response after a Type C meeting regarding the company’s planned biologics license application (BLA) submission for Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment… Read more . . .
-
Upsher-Smith has announced the US launch of Tosymra sumatriptan nasal spray. The FDA approved Tosymra for the treatment of migraine with or without aura in January 2019, and Upsher-Smith acquired US rights to the nasal… Read more . . .
-
AstraZeneca Canada has announced today that Health Canada has approved the use of Symbicort Turbuhaler budesonide/formoterol DPI as an anti-inflammatory reliever for the treatment of mild persistent asthma. According to the company, the expanded use was based on… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA